Twelve-month mortality from the “How Effective are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention (HEAT-PPCI) Trial”

There is ongoing uncertainty regarding the safety and efficacy of unfractionated heparin and bivalirudin when used for systemic anticoagulation in patients undergoing primary percutaneous coronary intervention (PPCI). This paper reports 12-month mortality from the HEAT-PPCI randomised trial.

Source: International Journal of Cardiology - March 31, 2020 Category: Cardiology Authors: Sarah R. Blake, Adeel Shahzad, Ian Kemp, Christine Mars Dip, Keith Wilson, Rod H. Stables Source Type: research